Premium
Metabolite quantification and high‐field MRS in breast cancer
Author(s) -
Haddadin Ihab S.,
McIntosh Adeka,
Meisamy Sina,
Corum Curt,
Snyder Angela L. Styczynski,
Powell Nathaniel J.,
Nelson Michael T.,
Yee Douglas,
Garwood Michael,
Bolan Patrick J.
Publication year - 2009
Publication title -
nmr in biomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.278
H-Index - 114
eISSN - 1099-1492
pISSN - 0952-3480
DOI - 10.1002/nbm.1217
Subject(s) - breast cancer , in vivo , metabolite , medicine , choline , cancer , medical physics , biology , microbiology and biotechnology
Abstract In vivo 1 H MRS is rapidly developing as a clinical tool for diagnosing and characterizing breast cancers. Many in vivo and in vitro experiments have demonstrated that alterations in concentrations of choline‐containing metabolites are associated with malignant transformation. In recent years, considerable efforts have been made to evaluate the role of 1 H MRS measurements of total choline‐containing compounds in the management of patients with breast cancer. Current technological developments, including the use of high‐field MR scanners and quantitative spectroscopic analysis methods, promise to increase the sensitivity and accuracy of breast MRS. This article reviews the literature describing in vivo MRS in breast cancer, with an emphasis on the development of high‐field MR scanning and quantitative methods. Potential applications of these technologies for diagnosing suspicious lesions and monitoring response to chemotherapy are discussed. Copyright © 2008 John Wiley & Sons, Ltd.